223 related articles for article (PubMed ID: 30405097)
1. Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study.
Fotiou D; Sergentanis TN; Papageorgiou L; Stamatelopoulos K; Gavriatopoulou M; Kastritis E; Psaltopoulou T; Salta S; Van Dreden P; Sangare R; Larsen AK; Terpos E; Elalamy I; Dimopoulos MA; Gerotziafas GT
Blood Cancer J; 2018 Nov; 8(11):102. PubMed ID: 30405097
[TBL] [Abstract][Full Text] [Related]
2. Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.
Syrigos K; Grapsa D; Sangare R; Evmorfiadis I; Larsen AK; Van Dreden P; Boura P; Charpidou A; Kotteas E; Sergentanis TN; Elalamy I; Falanga A; Gerotziafas GT
Oncologist; 2018 Nov; 23(11):1372-1381. PubMed ID: 30104289
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers for the diagnosis of venous thromboembolism: D-dimer, thrombin generation, procoagulant phospholipid and soluble P-selectin.
Riva N; Vella K; Hickey K; Bertù L; Zammit D; Spiteri S; Kitchen S; Makris M; Ageno W; Gatt A
J Clin Pathol; 2018 Nov; 71(11):1015-1022. PubMed ID: 30093507
[TBL] [Abstract][Full Text] [Related]
4. Enhanced thrombin generation detected with ST-Genesia analyzer in patients with newly diagnosed multiple myeloma.
Velasco-Rodríguez D; Martínez-Alfonzo I; Velasco-Valdazo AE; Revilla N; Mahíllo-Fernández I; Askari E; Castro-Quismondo N; Laso RV; Domingo-González A; Serrano-López J; Prieto E; Rosado B; Blanchard MJ; Martín-Herrero S; García-Raso A; Bueno MÁ; de la Plaza R; Peñaherrera M; López IG; López-Jiménez J; Martínez-López J; Llamas-Sillero P
J Thromb Thrombolysis; 2023 Apr; 55(3):464-473. PubMed ID: 36630029
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10.
Kovacs MJ; Davies GA; Chapman JA; Bahlis N; Voralia M; Roy J; Kouroukis CT; Chen C; Belch A; Reece D; Zhu L; Meyer RM; Shepherd L; Stewart KA
Br J Haematol; 2015 Feb; 168(4):511-7. PubMed ID: 25302852
[TBL] [Abstract][Full Text] [Related]
6. Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma.
Tiong IS; Rodgers SE; Lee CH; McRae SJ
Leuk Lymphoma; 2017 Apr; 58(4):941-949. PubMed ID: 27931131
[TBL] [Abstract][Full Text] [Related]
7. Prospective Assessment of Biomarkers of Hypercoagulability for the Identification of Patients With Severe Coronary Artery Disease. The ROADMAP-CAD Study.
Gerotziafas GT; Zografos T; Pantos I; Lefkou E; Carlo A; Fareed J; Van Dreden P; Katritsis D
Clin Appl Thromb Hemost; 2020; 26():1076029620964590. PubMed ID: 33284037
[TBL] [Abstract][Full Text] [Related]
8. Extracellular vesicle-associated procoagulant phospholipid and tissue factor activity in multiple myeloma.
Nielsen T; Kristensen SR; Gregersen H; Teodorescu EM; Christiansen G; Pedersen S
PLoS One; 2019; 14(1):e0210835. PubMed ID: 30640949
[TBL] [Abstract][Full Text] [Related]
9. PO-53 - Prospective evaluation of risk assessment models and biological markers of hypercoagulability for the identification of high VTE risk patients with lung adenocarcinoma. The ROADMAP study.
Boura P; Evmorfiadis I; Rousseau A; Charpidou A; Giozos G; Van Dreden P; Syrigos K; Larsen A; Elalamy I; Gerotziafas GT
Thromb Res; 2016 Apr; 140 Suppl 1():S196. PubMed ID: 27161741
[TBL] [Abstract][Full Text] [Related]
10. Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial.
Orsi FA; Biedermann JS; Kruip MJHA; van der Meer FJ; Rosendaal FR; van Hylckama Vlieg A; Bos MHA; Leebeek FWG; Cannegieter SC; Lijfering WM
J Thromb Haemost; 2019 Feb; 17(2):319-328. PubMed ID: 30565854
[TBL] [Abstract][Full Text] [Related]
11. Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS).
Posch F; Thaler J; Zlabinger GJ; Königsbrügge O; Koder S; Zielinski C; Pabinger I; Ay C
Clin Cancer Res; 2016 Jan; 22(1):200-6. PubMed ID: 26302981
[TBL] [Abstract][Full Text] [Related]
12. Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.
Chaari M; Ayadi I; Rousseau A; Lefkou E; Van Dreden P; Sidibe F; Ketatni H; Galea V; Khaterchi A; Bouzguenda R; Frikha M; Ghorbal L; Daoud J; Kallel C; Quinn M; Gligorov J; Lotz JP; Hatmi M; Elalamy I; Gerotziafas GT
BMC Cancer; 2014 Dec; 14():991. PubMed ID: 25535397
[TBL] [Abstract][Full Text] [Related]
13. Early thrombin formation capacity in trauma patients and association with venous thromboembolism.
Voils SA; Lemon SJ; Jordan J; Riley P; Frye R
Thromb Res; 2016 Nov; 147():13-15. PubMed ID: 27664391
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.
Anaissie EJ; Coleman EA; Goodwin JA; Kennedy RL; Lockhart KD; Stewart CB; Coon SK; Bailey C; Barlogie B
Cancer; 2012 Jan; 118(2):549-57. PubMed ID: 21720994
[TBL] [Abstract][Full Text] [Related]
15. Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy.
Abu Saadeh F; Langhe R; Galvin DM; O Toole SA; O'Donnell DM; Gleeson N; Norris LA
Thromb Res; 2016 Mar; 139():135-41. PubMed ID: 26916311
[TBL] [Abstract][Full Text] [Related]
16. The endogenous thrombin potential and the risk of venous thromboembolism.
Tripodi A; Martinelli I; Chantarangkul V; Battaglioli T; Clerici M; Mannucci PM
Thromb Res; 2007; 121(3):353-9. PubMed ID: 17560633
[TBL] [Abstract][Full Text] [Related]
17. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.
Sanfilippo KM; Luo S; Wang TF; Fiala M; Schoen M; Wildes TM; Mikhael J; Kuderer NM; Calverley DC; Keller J; Thomas T; Carson KR; Gage BF
Am J Hematol; 2019 Nov; 94(11):1176-1184. PubMed ID: 31379000
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients.
Schorling RM; Pfrepper C; Golombek T; Cella CA; Muñoz-Unceta N; Siegemund R; Engel C; Petros S; Lordick F; Knödler M
Oncol Res Treat; 2020; 43(9):414-427. PubMed ID: 32580190
[TBL] [Abstract][Full Text] [Related]
19. Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study.
van Doormaal F; Kleinjan A; Berckmans RJ; Mackman N; Manly D; Kamphuisen PW; Richel DJ; Büller HR; Sturk A; Nieuwland R
Thromb Haemost; 2012 Jul; 108(1):160-5. PubMed ID: 22535219
[TBL] [Abstract][Full Text] [Related]
20. Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable.
Hilhorst M; Winckers K; Wilde B; van Oerle R; ten Cate H; Tervaert JW
J Rheumatol; 2013 Dec; 40(12):2042-6. PubMed ID: 24128780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
